Profil
Nuket Desem worked as a Senior Manager of Development & Regulatory Affairs at Alterity Therapeutics Ltd., Vice President of Clinical & Regulatory Affairs at Spinifex Pharmaceuticals Pty Ltd., Principal at CSL Ltd., Senior Associate at Kendle Pty Ltd., Development Director at Percheron Therapeutics Ltd., and Director of Clinical & Regulatory Affairs at Percheron Therapeutics Ltd.
and Paranta Biosciences Ltd.
Desem holds an MBA from Monash University and an undergraduate degree from LaTrobe University.
Ehemalige bekannte Positionen von Nuket Desem
Unternehmen | Position | Ende |
---|---|---|
PERCHERON THERAPEUTICS LIMITED | Chief Tech/Sci/R&D Officer | 05.05.2023 |
PERCHERON THERAPEUTICS LIMITED | Corporate Officer/Principal | 31.08.2010 |
ALTERITY THERAPEUTICS LIMITED | General Counsel | - |
Paranta Biosciences Ltd.
Paranta Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Paranta Biosciences Ltd. engages in the research and development of novel biotherapeutic. t develops PB01 (recombinant human follistatin-288) for the treatment of fibrotic and inflammatory diseases. The company was founded in 2011 and is headquartered in Richmond, Australia. | Chief Tech/Sci/R&D Officer | - |
CSL LIMITED | Corporate Officer/Principal | - |
Ausbildung von Nuket Desem
Monash University | Masters Business Admin |
LaTrobe University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
CSL LIMITED | Health Technology |
PERCHERON THERAPEUTICS LIMITED | Health Technology |
ALTERITY THERAPEUTICS LIMITED | Health Technology |
Private Unternehmen | 3 |
---|---|
Spinifex Pharmaceuticals Pty Ltd.
Spinifex Pharmaceuticals Pty Ltd. Pharmaceuticals: MajorHealth Technology Spinifex Pharmaceuticals Pty Ltd. discovers and develops new drugs for the treatment and management of pain. The firm conducts medicinal chemistry and drug discovery activities, preclinical and early-phase clinical studies before seeking a partnership with pharmaceutical company to complete clinical development, file for regulatory approval, and carry out marketing activities. The company was founded in June 2005 and is headquartered in Preston, Australia. | Health Technology |
Kendle Pty Ltd. | |
Paranta Biosciences Ltd.
Paranta Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Paranta Biosciences Ltd. engages in the research and development of novel biotherapeutic. t develops PB01 (recombinant human follistatin-288) for the treatment of fibrotic and inflammatory diseases. The company was founded in 2011 and is headquartered in Richmond, Australia. | Health Technology |